UNICREDIT BANK/CALL/BIOGEN IDEC/400/0.1/18.06.25 | Real-time BOERSE MUENCHEN 11:42:02 2024-05-17 EDT | ||
| 0.54 EUR | -1.82% |
|
| Current month | +89.66% | ||
| 1 month | +223.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.54 | -1.82% |
| 24-05-16 | 0.55 | -1.79% |
| 24-05-15 | 0.56 | +30.23% |
| 24-05-14 | 0.43 | +2.38% |
| 24-05-13 | 0.42 | +23.53% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 11:42 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC7N1J |
| ISIN | DE000HC7N1J2 |
| Date issued | 2023-06-23 |
| Strike | 400 $ |
| Maturity | 2025-06-18 (397 Days) |
| Parity | 10 : 1 |
| Emission price | 3.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.28 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.05 € |
| Spread % | 8.93% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230
USD
Average target price
285.9
USD
Spread / Average Target
+24.29%
- Stock Market
- Warrants
- Warrant
